Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Inflammatory Bowel Disease-Pipeline Review, H1 2015

Inflammatory Bowel Disease-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Inflammatory Bowel Disease-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Inflammatory Bowel Disease-Pipeline Review, H1 2015', provides an overview of the Inflammatory Bowel Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Inflammatory Bowel Disease pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 9

Inflammatory Bowel Disease Overview 10

Therapeutics Development 11

Inflammatory Bowel Disease-Therapeutics under Development by Companies 13

Inflammatory Bowel Disease-Therapeutics under Investigation by Universities/Institutes 26

Inflammatory Bowel Disease-Pipeline Products Glance 29

Inflammatory Bowel Disease-Products under Development by Companies 33

Inflammatory Bowel Disease-Products under Investigation by Universities/Institutes 50

Inflammatory Bowel Disease-Companies Involved in Therapeutics Development 52

Inflammatory Bowel Disease-Therapeutics Assessment 187

Drug Profiles 210

Inflammatory Bowel Disease-Recent Pipeline Updates 552

Inflammatory Bowel Disease-Dormant Projects 678

Inflammatory Bowel Disease-Discontinued Products 699

Inflammatory Bowel Disease-Product Development Milestones 702

Appendix 712

List of Tables

Number of Products under Development for Inflammatory Bowel Disease, H1 2015 39

Number of Products under Development for Inflammatory Bowel Disease-Comparative Analysis, H1 2015 40

Number of Products under Development by Companies, H1 2015 42

Number of Products under Development by Companies, H1 2015 (Contd..1) 43

Number of Products under Development by Companies, H1 2015 (Contd..2) 44

Number of Products under Development by Companies, H1 2015 (Contd..3) 45

Number of Products under Development by Companies, H1 2015 (Contd..4) 46

Number of Products under Development by Companies, H1 2015 (Contd..5) 47

Number of Products under Development by Companies, H1 2015 (Contd..6) 48

Number of Products under Development by Companies, H1 2015 (Contd..7) 49

Number of Products under Development by Companies, H1 2015 (Contd..8) 50

Number of Products under Development by Companies, H1 2015 (Contd..9) 51

Number of Products under Development by Companies, H1 2015 (Contd..10) 52

Number of Products under Development by Companies, H1 2015 (Contd..11) 53

Number of Products under Investigation by Universities/Institutes, H1 2015 55

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 56

Comparative Analysis by Late Stage Development, H1 2015 57

Comparative Analysis by Clinical Stage Development, H1 2015 58

Comparative Analysis by Early Stage Development, H1 2015 59

Comparative Analysis by Unknown Stage Development, H1 2015 60

Products under Development by Companies, H1 2015 61

Products under Development by Companies, H1 2015 (Contd..1) 62

Products under Development by Companies, H1 2015 (Contd..2) 63

Products under Development by Companies, H1 2015 (Contd..3) 64

Products under Development by Companies, H1 2015 (Contd..4) 65

Products under Development by Companies, H1 2015 (Contd..5) 66

Products under Development by Companies, H1 2015 (Contd..6) 67

Products under Development by Companies, H1 2015 (Contd..7) 68

Products under Development by Companies, H1 2015 (Contd..8) 69

Products under Development by Companies, H1 2015 (Contd..9) 70

Products under Development by Companies, H1 2015 (Contd..10) 71

Products under Development by Companies, H1 2015 (Contd..11) 72

Products under Development by Companies, H1 2015 (Contd..12) 73

Products under Development by Companies, H1 2015 (Contd..13) 74

Products under Development by Companies, H1 2015 (Contd..14) 75

Products under Development by Companies, H1 2015 (Contd..15) 76

Products under Development by Companies, H1 2015 (Contd..16) 77

Products under Investigation by Universities/Institutes, H1 2015 78

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 79

Inflammatory Bowel Disease-Pipeline by 4SC AG, H1 2015 80

Inflammatory Bowel Disease-Pipeline by AB Science, H1 2015 81

Inflammatory Bowel Disease-Pipeline by AbbVie Inc., H1 2015 82

Inflammatory Bowel Disease-Pipeline by Advinus Therapeutics Ltd., H1 2015 83

Inflammatory Bowel Disease-Pipeline by Aerpio Therapeutics, Inc., H1 2015 84

Inflammatory Bowel Disease-Pipeline by Alba Therapeutics Corporation, H1 2015 85

Inflammatory Bowel Disease-Pipeline by AlbireoPharma, H1 2015 86

Inflammatory Bowel Disease-Pipeline by Alfa Wassermann S.p.A, H1 2015 87

Inflammatory Bowel Disease-Pipeline by Allozyne, Inc., H1 2015 88

Inflammatory Bowel Disease-Pipeline by Altheus Therapeutics, Inc., H1 2015 89

Inflammatory Bowel Disease-Pipeline by Alvine Pharmaceuticals, Inc., H1 2015 90

Inflammatory Bowel Disease-Pipeline by Am-Pharma B.V., H1 2015 91

Inflammatory Bowel Disease-Pipeline by Amakem NV, H1 2015 92

Inflammatory Bowel Disease-Pipeline by Amgen Inc., H1 2015 93

Inflammatory Bowel Disease-Pipeline by Amorepacific Corporation, H1 2015 94

Inflammatory Bowel Disease-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 95

Inflammatory Bowel Disease-Pipeline by Apogee Biotechnology Corporation, H1 2015 96

Inflammatory Bowel Disease-Pipeline by Ardelyx, Inc., H1 2015 97

Inflammatory Bowel Disease-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 98

Inflammatory Bowel Disease-Pipeline by Argos Therapeutics, Inc., H1 2015 99

Inflammatory Bowel Disease-Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2015 100

Inflammatory Bowel Disease-Pipeline by AstraZeneca Plc, H1 2015 101

Inflammatory Bowel Disease-Pipeline by Avaxia Biologics, Inc., H1 2015 102

Inflammatory Bowel Disease-Pipeline by Axxam SpA, H1 2015 103

Inflammatory Bowel Disease-Pipeline by Basilea Pharmaceutica AG, H1 2015 104

Inflammatory Bowel Disease-Pipeline by BIOCAD, H1 2015 105

Inflammatory Bowel Disease-Pipeline by BioLineRx, Ltd., H1 2015 106

Inflammatory Bowel Disease-Pipeline by Biotec Pharmacon ASA, H1 2015 107

Inflammatory Bowel Disease-Pipeline by BioTherapeutics Inc., H1 2015 108

Inflammatory Bowel Disease-Pipeline by Blueberry Therapeutics Ltd, H1 2015 109

Inflammatory Bowel Disease-Pipeline by Boehringer Ingelheim GmbH, H1 2015 110

Inflammatory Bowel Disease-Pipeline by Bristol-Myers Squibb Company, H1 2015 111

Inflammatory Bowel Disease-Pipeline by Calypso Biotech SA, H1 2015 112

Inflammatory Bowel Disease-Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 113

Inflammatory Bowel Disease-Pipeline by Celgene Corporation, H1 2015 114

Inflammatory Bowel Disease-Pipeline by Celltrion, Inc., H1 2015 115

Inflammatory Bowel Disease-Pipeline by Celsus Therapeutics Plc, H1 2015 116

Inflammatory Bowel Disease-Pipeline by ChemoCentryx, Inc., H1 2015 117

Inflammatory Bowel Disease-Pipeline by ChironWells GmbH, H1 2015 118

Inflammatory Bowel Disease-Pipeline by CLL Pharma, H1 2015 119

Inflammatory Bowel Disease-Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 120

Inflammatory Bowel Disease-Pipeline by Creabilis SA, H1 2015 121

Inflammatory Bowel Disease-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 122

Inflammatory Bowel Disease-Pipeline by DBV Technologies S.A., H1 2015 123

Inflammatory Bowel Disease-Pipeline by Delenex Therapeutics AG, H1 2015 124

Inflammatory Bowel Disease-Pipeline by Dr. Falk Pharma GmbH, H1 2015 125

Inflammatory Bowel Disease-Pipeline by Effimune SAS, H1 2015 126

Inflammatory Bowel Disease-Pipeline by Eisai Co., Ltd., H1 2015 127

Inflammatory Bowel Disease-Pipeline by Eli Lilly and Company, H1 2015 128

Inflammatory Bowel Disease-Pipeline by Emergent BioSolutions Inc., H1 2015 129

Inflammatory Bowel Disease-Pipeline by Enlivex Therapeutics Ltd, H1 2015 130

Inflammatory Bowel Disease-Pipeline by Enzo Biochem, Inc., H1 2015 131

Inflammatory Bowel Disease-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 132

Inflammatory Bowel Disease-Pipeline by Farmacija d.o.o. Tuzla, H1 2015 133

Inflammatory Bowel Disease-Pipeline by Ferring International Center S.A., H1 2015 134

Inflammatory Bowel Disease-Pipeline by FibroGen, Inc., H1 2015 135

Inflammatory Bowel Disease-Pipeline by Galapagos NV, H1 2015 136

Inflammatory Bowel Disease-Pipeline by Genentech, Inc., H1 2015 137

Inflammatory Bowel Disease-Pipeline by Genfit SA, H1 2015 138

Inflammatory Bowel Disease-Pipeline by Genor BioPharma Co., Ltd., H1 2015 139

Inflammatory Bowel Disease-Pipeline by Gilead Sciences, Inc., H1 2015 140

Inflammatory Bowel Disease-Pipeline by GlaxoSmithKline Plc, H1 2015 141

Inflammatory Bowel Disease-Pipeline by GlycoMar Limited, H1 2015 142

Inflammatory Bowel Disease-Pipeline by iCo Therapeutics Inc., H1 2015 143

Inflammatory Bowel Disease-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 144

Inflammatory Bowel Disease-Pipeline by Immune Response BioPharma, Inc., H1 2015 145

Inflammatory Bowel Disease-Pipeline by ImmusanT, Inc., H1 2015 146

Inflammatory Bowel Disease-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 147

Inflammatory Bowel Disease-Pipeline by Innovent Biologics, Inc., H1 2015 148

Inflammatory Bowel Disease-Pipeline by Intrexon Corporation, H1 2015 149

Inflammatory Bowel Disease-Pipeline by Jenrin Discovery, Inc., H1 2015 150

Inflammatory Bowel Disease-Pipeline by Johnson & Johnson, H1 2015 151

Inflammatory Bowel Disease-Pipeline by Kineta, Inc., H1 2015 152

Inflammatory Bowel Disease-Pipeline by Kymab Limited, H1 2015 153

Inflammatory Bowel Disease-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 154

Inflammatory Bowel Disease-Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2015 155

Inflammatory Bowel Disease-Pipeline by Lead Pharma Holding B.V., H1 2015 156

Inflammatory Bowel Disease-Pipeline by Lpath, Inc., H1 2015 157

Inflammatory Bowel Disease-Pipeline by Lycera Corp., H1 2015 158

Inflammatory Bowel Disease-Pipeline by Mabion SA, H1 2015 159

Inflammatory Bowel Disease-Pipeline by Medgenics Inc., H1 2015 160

Inflammatory Bowel Disease-Pipeline by Mesoblast Limited, H1 2015 161

Inflammatory Bowel Disease-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 162

Inflammatory Bowel Disease-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 163

Inflammatory Bowel Disease-Pipeline by Neovacs SA, H1 2015 164

Inflammatory Bowel Disease-Pipeline by Nivalis Therapeutics, Inc., H1 2015 165

Inflammatory Bowel Disease-Pipeline by Novozymes A/S, H1 2015 166

Inflammatory Bowel Disease-Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 167

Inflammatory Bowel Disease-Pipeline by Oncobiologics, Inc., H1 2015 168

Inflammatory Bowel Disease-Pipeline by Oncodesign SA, H1 2015 169

Inflammatory Bowel Disease-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 170

Inflammatory Bowel Disease-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 171

Inflammatory Bowel Disease-Pipeline by Opsona Therapeutics Limited, H1 2015 172

Inflammatory Bowel Disease-Pipeline by Pepscan Therapeutics, H1 2015 173

Inflammatory Bowel Disease-Pipeline by Pfenex Inc., H1 2015 174

Inflammatory Bowel Disease-Pipeline by Pfizer Inc., H1 2015 175

Inflammatory Bowel Disease-Pipeline by Pieris AG, H1 2015 176

Inflammatory Bowel Disease-Pipeline by Plexxikon Inc., H1 2015 177

Inflammatory Bowel Disease-Pipeline by Pluristem Therapeutics Inc., H1 2015 178

Inflammatory Bowel Disease-Pipeline by ProtAb Ltd, H1 2015 179

Inflammatory Bowel Disease-Pipeline by Protagonist Therapeutics Inc., H1 2015 180

Inflammatory Bowel Disease-Pipeline by Protalix BioTherapeutics, Inc., H1 2015 181

Inflammatory Bowel Disease-Pipeline by Provid Pharmaceuticals, Inc., H1 2015 182

Inflammatory Bowel Disease-Pipeline by Qu Biologics Inc., H1 2015 183

Inflammatory Bowel Disease-Pipeline by Receptos, Inc., H1 2015 184

Inflammatory Bowel Disease-Pipeline by RedHill Biopharma Ltd., H1 2015 185

Inflammatory Bowel Disease-Pipeline by ReveraGen BioPharma, Inc., H1 2015 186

Inflammatory Bowel Disease-Pipeline by Salix Pharmaceuticals Ltd., H1 2015 187

Inflammatory Bowel Disease-Pipeline by Sandoz International GmbH, H1 2015 188

Inflammatory Bowel Disease-Pipeline by Saniona AB, H1 2015 189

Inflammatory Bowel Disease-Pipeline by Sareum Holdings Plc, H1 2015 190

Inflammatory Bowel Disease-Pipeline by Selecta Biosciences, Inc., H1 2015 191

Inflammatory Bowel Disease-Pipeline by Selexys Pharmaceuticals Corporation, H1 2015 192

Inflammatory Bowel Disease-Pipeline by Sigmoid Pharma Limited, H1 2015 193

Inflammatory Bowel Disease-Pipeline by Sitari Pharmaceuticals, Inc., H1 2015 194

Inflammatory Bowel Disease-Pipeline by Soligenix, Inc., H1 2015 195

Inflammatory Bowel Disease-Pipeline by Spherium Biomed S.L., H1 2015 196

Inflammatory Bowel Disease-Pipeline by Stelic Institute & Co., H1 2015 197

Inflammatory Bowel Disease-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 198

Inflammatory Bowel Disease-Pipeline by Swecure AB, H1 2015 199

Inflammatory Bowel Disease-Pipeline by Sylentis S.A., H1 2015 200

Inflammatory Bowel Disease-Pipeline by Synovo GmbH, H1 2015 201

Inflammatory Bowel Disease-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 202

Inflammatory Bowel Disease-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 203

Inflammatory Bowel Disease-Pipeline by Tiziana Life Sciences Plc, H1 2015 204

Inflammatory Bowel Disease-Pipeline by Tolerys SA, H1 2015 205

Inflammatory Bowel Disease-Pipeline by Toray Industries, Inc., H1 2015 206

Inflammatory Bowel Disease-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 207

Inflammatory Bowel Disease-Pipeline by Trino Therapeutics Limited, H1 2015 208

Inflammatory Bowel Disease-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 209

Inflammatory Bowel Disease-Pipeline by Ventria Bioscience, H1 2015 210

Inflammatory Bowel Disease-Pipeline by VG Life Sciences, Inc., H1 2015 211

Inflammatory Bowel Disease-Pipeline by Virobay Inc., H1 2015 212

Inflammatory Bowel Disease-Pipeline by Winston Pharmaceuticals, Inc., H1 2015 213

Inflammatory Bowel Disease-Pipeline by Zedira GmbH, H1 2015 214

Assessment by Monotherapy Products, H1 2015 215

Assessment by Combination Products, H1 2015 216

Number of Products by Stage and Target, H1 2015 218

Number of Products by Stage and Mechanism of Action, H1 2015 227

Number of Products by Stage and Route of Administration, H1 2015 235

Number of Products by Stage and Molecule Type, H1 2015 237

Inflammatory Bowel Disease Therapeutics-Recent Pipeline Updates, H1 2015 579

Inflammatory Bowel Disease-Dormant Projects, H1 2015 705

Inflammatory Bowel Disease-Dormant Projects (Contd..1), H1 2015 706

Inflammatory Bowel Disease-Dormant Projects (Contd..2), H1 2015 707

Inflammatory Bowel Disease-Dormant Projects (Contd..3), H1 2015 708

Inflammatory Bowel Disease-Dormant Projects (Contd..4), H1 2015 709

Inflammatory Bowel Disease-Dormant Projects (Contd..5), H1 2015 710

Inflammatory Bowel Disease-Dormant Projects (Contd..6), H1 2015 711

Inflammatory Bowel Disease-Dormant Projects (Contd..7), H1 2015 712

Inflammatory Bowel Disease-Dormant Projects (Contd..8), H1 2015 713

Inflammatory Bowel Disease-Dormant Projects (Contd..9), H1 2015 714

Inflammatory Bowel Disease-Dormant Projects (Contd..10), H1 2015 715

Inflammatory Bowel Disease-Dormant Projects (Contd..11), H1 2015 716

Inflammatory Bowel Disease-Dormant Projects (Contd..12), H1 2015 717

Inflammatory Bowel Disease-Dormant Projects (Contd..13), H1 2015 718

Inflammatory Bowel Disease-Dormant Projects (Contd..14), H1 2015 719

Inflammatory Bowel Disease-Dormant Projects (Contd..15), H1 2015 720

Inflammatory Bowel Disease-Dormant Projects (Contd..16), H1 2015 721

Inflammatory Bowel Disease-Dormant Projects (Contd..17), H1 2015 722

Inflammatory Bowel Disease-Dormant Projects (Contd..18), H1 2015 723

Inflammatory Bowel Disease-Dormant Projects (Contd..19), H1 2015 724

Inflammatory Bowel Disease-Dormant Projects (Contd..20), H1 2015 725

Inflammatory Bowel Disease-Discontinued Products, H1 2015 726

Inflammatory Bowel Disease-Discontinued Products (Contd..1), H1 2015 727

Inflammatory Bowel Disease-Discontinued Products (Contd..2), H1 2015 728

List of Figures

Number of Products under Development for Inflammatory Bowel Disease, H1 2015 39

Number of Products under Development for Inflammatory Bowel Disease-Comparative Analysis, H1 2015 40

Number of Products under Development by Companies, H1 2015 41

Number of Products under Investigation by Universities/Institutes, H1 2015 54

Comparative Analysis by Late Stage Development, H1 2015 57

Comparative Analysis by Clinical Stage Development, H1 2015 58

Comparative Analysis by Early Stage Products, H1 2015 59

Assessment by Monotherapy Products, H1 2015 215

Assessment by Combination Products, H1 2015 216

Number of Products by Top 10 Targets, H1 2015 217

Number of Products by Stage and Top 10 Targets, H1 2015 217

Number of Products by Top 10 Mechanism of Actions, H1 2015 226

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 226

Number of Products by Top 10 Routes of Administration, H1 2015 234

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 234

Number of Products by Top 10 Molecule Types, H1 2015 236

Number of Products by Stage and Top 10 Molecule Types, H1 2015 236

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science

AbbVie Inc.

Advinus Therapeutics Ltd.

Aerpio Therapeutics, Inc.

Alba Therapeutics Corporation

AlbireoPharma

Alfa Wassermann S.p.A

Allozyne, Inc.

Altheus Therapeutics, Inc.

Alvine Pharmaceuticals, Inc.

Am-Pharma B.V.

Amakem NV

Amgen Inc.

Amorepacific Corporation

Ampio Pharmaceuticals, Inc.

Apogee Biotechnology Corporation

Ardelyx, Inc.

Arena Pharmaceuticals, Inc.

Argos Therapeutics, Inc.

ASKA Pharmaceutical Co., Ltd.

AstraZeneca Plc

Avaxia Biologics, Inc.

Axxam SpA

Basilea Pharmaceutica AG

BIOCAD

BioLineRx, Ltd.

Biotec Pharmacon ASA

BioTherapeutics Inc.

Blueberry Therapeutics Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calypso Biotech SA

Catabasis Pharmaceuticals, Inc.

Celgene Corporation

Celltrion, Inc.

Celsus Therapeutics Plc

ChemoCentryx, Inc.

ChironWells GmbH

CLL Pharma

Cosmo Pharmaceuticals S.p.A

Creabilis SA

Daiichi Sankyo Company, Limited

DBV Technologies S.A.

Delenex Therapeutics AG

Dr. Falk Pharma GmbH

Effimune SAS

Eisai Co., Ltd.

Eli Lilly and Company

Emergent BioSolutions Inc.

Enlivex Therapeutics Ltd

Enzo Biochem, Inc.

Epirus Biopharmaceuticals, Inc.

Farmacija d.o.o. Tuzla

Ferring International Center S.A.

FibroGen, Inc.

Galapagos NV

Genentech, Inc.

Genfit SA

Genor BioPharma Co., Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

GlycoMar Limited

iCo Therapeutics Inc.

Idera Pharmaceuticals, Inc.

Immune Response BioPharma, Inc.

ImmusanT, Inc.

Inbiopro Solutions Pvt. Ltd.

Innovent Biologics, Inc.

Intrexon Corporation

Jenrin Discovery, Inc.

Johnson & Johnson

Kineta, Inc.

Kymab Limited

Kyorin Pharmaceutical Co., Ltd.

Kytogenics Pharmaceuticals, Inc.

Lead Pharma Holding B.V.

Lpath, Inc.

Lycera Corp.

Mabion SA

Medgenics Inc.

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

Momenta Pharmaceuticals, Inc.

Neovacs SA

Nivalis Therapeutics, Inc.

Novozymes A/S

Omni Bio Pharmaceutical Inc.

Oncobiologics, Inc.

Oncodesign SA

Ono Pharmaceutical Co., Ltd.

Onyx Pharmaceuticals, Inc.

Opsona Therapeutics Limited

Pepscan Therapeutics

Pfenex Inc.

Pfizer Inc.

Pieris AG

Plexxikon Inc.

Pluristem Therapeutics Inc.

ProtAb Ltd

Protagonist Therapeutics Inc.

Protalix BioTherapeutics, Inc.

Provid Pharmaceuticals, Inc.

Qu Biologics Inc.

Receptos, Inc.

RedHill Biopharma Ltd.

ReveraGen BioPharma, Inc.

Salix Pharmaceuticals Ltd.

Sandoz International GmbH

Saniona AB

Sareum Holdings Plc

Selecta Biosciences, Inc.

Selexys Pharmaceuticals Corporation

Sigmoid Pharma Limited

Sitari Pharmaceuticals, Inc.

Soligenix, Inc.

Spherium Biomed S.L.

Stelic Institute & Co.

Sucampo Pharmaceuticals, Inc.

Swecure AB

Sylentis S.A.

Synovo GmbH

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Limited

Tiziana Life Sciences Plc

Tolerys SA

Toray Industries, Inc.

Torrent Pharmaceuticals Limited

Trino Therapeutics Limited

Upsher-Smith Laboratories, Inc.

Ventria Bioscience

VG Life Sciences, Inc.

Virobay Inc.

Winston Pharmaceuticals, Inc.

Zedira GmbH

Inflammatory Bowel Disease Therapeutic Products under Development, Key Players in Inflammatory Bowel Disease Therapeutics, Inflammatory Bowel Disease Pipeline Overview, Inflammatory Bowel Disease Pipeline, Inflammatory Bowel Disease Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com